The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials-Reference-Cited by-同舟云学术

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials

Published:2017-12-06 Issue:6 Volume:124 Page:1197-1206
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

de Koning Harry J.¹,Gulati Roman²^ORCID,Moss Sue M.³,Hugosson Jonas⁴,Pinsky Paul F.⁵,Berg Christine D.⁶,Auvinen Anssi⁷,Andriole Gerald L.⁸,Roobol Monique J.⁹,Crawford E. David¹⁰,Nelen Vera¹¹,Kwiatkowski Maciej¹²,Zappa Marco¹³,Luján Marcos¹⁴,Villers Arnauld¹⁵,de Carvalho Tiago M.¹^ORCID,Feuer Eric J.¹⁶,Tsodikov Alex¹⁷,Mariotto Angela B.¹⁶,Heijnsdijk Eveline A. M.¹^ORCID,Etzioni Ruth²

Affiliation:

1. Department of Public Health; Erasmus Medical Center; Rotterdam the Netherlands

2. Division of Public Health Sciences; Fred Hutchinson Cancer Research Institute; Seattle Washington

3. Wolfson Institute; Queen Mary University of London; London United Kingdom

4. Department of Urology; Sahlgrenska University Hospital; Goteborg Sweden

5. Division of Cancer Prevention, National Cancer Institute; Bethesda Maryland

6. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine; Baltimore Maryland

7. School of Health Sciences; University of Tampere; Tampere Finland

8. Division of Urologic Surgery, Department of Surgery; Washington University School of Medicine; St. Louis Missouri

9. Department of Urology; Erasmus Medical Center; Rotterdam the Netherlands

10. Urologic Oncology; University of Colorado; Denver Colorado

11. Provinciaal Instituut voor Hygiene; Antwerp Belgium

12. Department of Urology; Aarau Canton Hospital; Aarau Switzerland

13. Unit of Epidemiology, Institute for Cancer Prevention; Florence Italy

14. Urology Service, Infanta Cristina University Hospital; Complutense University of Madrid; Parla Madrid Spain

15. Department of Urology; Regional University Hospital Center; Lille France

16. Division of Cancer Control and Population Sciences, National Cancer Institute; Bethesda Maryland

17. Department of Biostatistics; University of Michigan; Ann Arbor Michigan

Funder

National Cancer Institute

Cancer Intervention and Surveillance Modeling Network (CISNET)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference32 articles.

1. Screening and prostate-cancer mortality in a randomized European study;Schroder;N Engl J Med,2009

2. Prostate-cancer mortality at 11 years of follow-up;Schroder;N Engl J Med,2012

3. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schroder;Lancet,2014

4. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up;Andriole;J Natl Cancer Inst,2012

5. Screening for prostate cancer-the controversy that refuses to die;Barry;N Engl J Med,2009

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors;JNCI Monographs;2023-11-01

2. Prostate cancer screening—stepping forward with MRI;European Radiology;2023-05-08

3. Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for Prostate-Specific Antigen Levels in Men Without Prostate Cancer;2023-05-05

4. Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial;Journal of Urology;2022-11

5. Design and Implementation of Taizhou Integrated Prostate Screening;American Journal of Men's Health;2022-11